Skip to main content
SpringerLink
Log in

Skeletal Complications of Malignancy: Central Role for the Osteoclast

  • Chapter
Bone Resorption

Part of the book series: Topics in Bone Biology ((TBB,volume 2))

  • 1038 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abou-Samra AB, Juppner H, Force T, Freeman MW, Kong XF, Schipani E, et al. (1992) Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89(7):2732–6.

    Article  PubMed  CAS  Google Scholar 

  2. Adams JS, Sharma OP, Gacad MA, Singer FR (1983) Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. Journal of Clinical Investigation 72(5):1856–60.

    Article  PubMed  CAS  ISI  Google Scholar 

  3. Arguello F, Baggs RB, Frantz CN (1998) A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48:6876–81.

    Google Scholar 

  4. Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62:7203–6.

    PubMed  CAS  ISI  Google Scholar 

  5. Barhoum M, Hutchins L, Fonseca VA (1999) Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. American Journal of the Medical Sciences 318(3):203–5.

    Article  PubMed  CAS  ISI  Google Scholar 

  6. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW, Suva LJ (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62:5571–9.

    PubMed  CAS  ISI  Google Scholar 

  7. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Guercio S, Torta M, Tampellini M, Dovio A, Poggio M, Scarpa RM, Angeli A (2002) Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 17:244–52.

    PubMed  CAS  Google Scholar 

  8. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319(6053):516–18.

    Article  PubMed  CAS  ISI  Google Scholar 

  9. Binstock ML, Mundy GR (1981) Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy. Annals of Internal Medicine 93(2):269–72.

    ISI  Google Scholar 

  10. Bisaz S, Jung A, Fleisch H (1978) Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 54:265–72.

    PubMed  CAS  Google Scholar 

  11. Black K, Garrett IR, Mundy GR (1991). Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128(5):2657–9.

    PubMed  CAS  ISI  Google Scholar 

  12. Black MH, Diamandis EP (2000) The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat 59:1–14.

    Article  PubMed  CAS  Google Scholar 

  13. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97(3 Suppl):887–92.

    Article  PubMed  ISI  Google Scholar 

  14. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949–54.

    PubMed  CAS  ISI  Google Scholar 

  15. Botella A, Rekik M, Delvaux M, Davicco MJ, Barlet JP, Frexinos J, et al. (1994) Parathyroid hormone (PTH) and PTH-related peptide induce relaxation of smooth muscle cells from guinea pig ileum: interaction with vasoactive intestinal peptide receptors. Endocrinology 135(5):2160–7.

    Article  PubMed  CAS  ISI  Google Scholar 

  16. Boxer DI, Todd CE, Coleman R, Fogelman I (1989) Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 30:1318–20.

    PubMed  CAS  Google Scholar 

  17. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125(3):1142–50.

    PubMed  CAS  ISI  Google Scholar 

  18. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR (1986) Scanning electron microscopy in bone pathology: Review of methods. Potential and applications. Scanning Electron Microscopy IV:1537–54.

    Google Scholar 

  19. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CY (1984) Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Annals of Internal Medicine 100(1):1–6.

    PubMed  CAS  ISI  Google Scholar 

  20. Buchs N, Manen D, Bonjour JP, Rizzoli R (2000) Calcium stimulates parathyroid hormone-related protein production in Leydig tumor cells through a putative cation-sensing mechanism. Eur J Endocrinol 142:500–5.

    Article  PubMed  CAS  Google Scholar 

  21. Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG (1991) Parathyroid hormone related protein and hypercalcaemia in breast cancer. British Medical Journal 303(6816):1506–9.

    Article  PubMed  CAS  ISI  Google Scholar 

  22. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG (1992) Parathyroid hormone related protein and skeletal morbidity in breast cancer. European Journal of Cancer 28(2–3):690–2.

    Article  PubMed  CAS  Google Scholar 

  23. Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP, Jr., Olson BR, et al. (1990) Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. New England Journal of Medicine 322(16):1106–12.

    Article  PubMed  CAS  ISI  Google Scholar 

  24. Burtis WJ, Wu T, Bunch C, Wysolmerski J, Insogna K, Weir E, Broadus AE, Stewart AF (1987) Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 262:7151–6.

    PubMed  CAS  Google Scholar 

  25. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563–72.

    Article  PubMed  CAS  Google Scholar 

  26. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51:918–24.

    Article  PubMed  CAS  ISI  Google Scholar 

  27. Chelouche Lev D, Price JE (2002) Therapeutic intervention with breast cancer metastasis. Crit Rev Eukaryot Gene Expr 12:137–50.

    Article  PubMed  Google Scholar 

  28. Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, Wang CY, et al. (2002) Parathyroid hormone and parathyroid hormone-related protein exert both pro-and anti-apoptotic effects in mesenchymal cells. Journal of Biological Chemistry 277(22):19374–81.

    Article  PubMed  CAS  ISI  Google Scholar 

  29. Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Exp 10:159–78.

    CAS  Google Scholar 

  30. Clezardin P (2002) The antitumor potential of bisphosphonates. Semin Oncol 29(6 Suppl 21):33–42.

    Article  PubMed  CAS  Google Scholar 

  31. Coffman JA (2003) Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 27:315–24.

    Article  PubMed  CAS  Google Scholar 

  32. Coleman RE, Rubens RD (1987) The clinical course of bone metastases from breast cancer. Brit J Cancer 55:61–6.

    PubMed  CAS  Google Scholar 

  33. Coleman RE (2002) Bisphosphonates for the prevention of bone metastases. Semin Oncol 29(6 Suppl 21):43–9.

    Article  PubMed  CAS  Google Scholar 

  34. Coleman RE (2003) Current and future status of adjuvant therapy for breast cancer. Cancer. 97(3 Suppl):880–6.

    Article  PubMed  ISI  Google Scholar 

  35. Coleman RE (2002) Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 25(6 Suppl 1):S25–31.

    Article  PubMed  Google Scholar 

  36. Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ (2003) Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 97(3 Suppl):739–47.

    Article  PubMed  ISI  CAS  Google Scholar 

  37. Cornish J, Naot D, Reid IR (2003) Adrenomedullin-a regulator of bone formation. Regul Pept 112:79–86.

    Article  PubMed  CAS  Google Scholar 

  38. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–92.

    Article  PubMed  CAS  ISI  Google Scholar 

  39. Cramer SD, Chen Z, Peehl DM (1996) Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156:526–31.

    Article  PubMed  CAS  Google Scholar 

  40. Dallas SL, Rosser JL, Mundy GR, Bonewald LF (2002) Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277:21352–60.

    Article  PubMed  CAS  Google Scholar 

  41. de la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, et al. (1995) Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein. Journal of Clinical Investigation 95(6):2846–52.

    Article  PubMed  Google Scholar 

  42. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15:955–62.

    PubMed  CAS  Google Scholar 

  43. Deyama Y, Takeyama S, Koshikawa M, Shirai Y, Yoshimura Y, Nishikata M, Suzuki K, Matsumoto A (2000) Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells. Biochem Biophys Res Commun 274:249–54.

    Article  PubMed  CAS  Google Scholar 

  44. Diel IJ, Solomayer EF, Bastert G (2000) Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88(12 Suppl):3080–8.

    Article  PubMed  CAS  Google Scholar 

  45. Diel IJ, Solomayer EF, Bastert G (2000) Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 1:43–51.

    Article  PubMed  CAS  Google Scholar 

  46. Dumont N, Arteaga CL (2003) Targeting the TGFß signaling network in human neoplasia. Cancer Cell 3:531–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  47. Eaton CL, Coleman RE (2003) Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 29:189–98.

    Article  PubMed  CAS  Google Scholar 

  48. Eilon G, Mundy GR (1978) Direct resorption of bone by human breast cancer cells in vitro. Nature 276:726–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  49. El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R (2000) The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60:4412–14.

    PubMed  Google Scholar 

  50. Felding-Habermann B, O’Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM (2001). Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 98:1853–8.

    Article  PubMed  CAS  Google Scholar 

  51. Fetchick DA, Bertolini DR, Sarin PS, Weintraub ST, Mundy GR, Dunn JF (1986) Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic virus-I-transformed lymphocytes. Journal of Clinical Investigation 78(2):592–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  52. Fidler IJ (2003) The pathogenesis of cancer metastasis: the “seed and soil” hypothesis revisited. Nat Rev Cancer 3:1–6.

    Article  CAS  Google Scholar 

  53. Fierabracci P, Pinchera A, Miccoli P, Conte PF, Vignali E, Zaccagnini M, et al. (2001) Increased prevalence of primary hyperparathyroidism in treated breast cancer. Journal of Endocrinological Investigation 24(5):315–20.

    PubMed  CAS  ISI  Google Scholar 

  54. Firkin F, Seymour JF, Watson AM, Grill V, Martin TJ (1996) Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. British Journal of Haematology 94(3):486–92.

    Article  PubMed  CAS  ISI  Google Scholar 

  55. Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42(6):919–44.

    Article  PubMed  CAS  ISI  Google Scholar 

  56. Fontana A, Delmas PD (2000) Markers of bone turnover in bone metastases. Cancer 88(12 Suppl):2952–60.

    Article  PubMed  CAS  Google Scholar 

  57. Fontana A, Delmas PD (2003) Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. Endocrinol Metab Clin North Am 32:219–32.

    Article  PubMed  CAS  Google Scholar 

  58. Frith JC, Rogers MJ (2003) Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18:204–12.

    Article  PubMed  CAS  Google Scholar 

  59. Fromigue O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 25:539–46.

    PubMed  CAS  Google Scholar 

  60. Fukumitsu N, Uchiyama M (2002) Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 51:814–18.

    Article  PubMed  CAS  ISI  Google Scholar 

  61. Funk JL, Lausier J, Moser AH, Shigenaga JK, Huling S, Nissenson RA, et al. (1995) Endotoxin induces parathyroid hormone-related protein gene expression in splenic stromal and smooth muscle cells, not in splenic lymphocytes. Endocrinology 136(8):3412–21.

    Article  PubMed  CAS  ISI  Google Scholar 

  62. Funk JL, Shigenaga JK, Moser AH, Krul EJ, Strewler GJ, Feingold KR, et al. (1994) Cytokine regulation of parathyroid hormone-related protein messenger ribonucleic acid levels in mouse spleen: paradoxical effects of interferon-gamma and interleukin-4. Endocrinology 135(1):351–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  63. Funk JL, Wei H (1998) Regulation of PTHrP expression in MCF-7 breast carcinoma cells by estrogen and antiestrogens. Biochem Biophys Res Commun 251:849–54.

    Article  PubMed  CAS  Google Scholar 

  64. Galasko CS (1986) Skeletal metastases. Clin Orthop 210:18–30.

    PubMed  Google Scholar 

  65. Gallwitz WE, Guise TA, Mundy GR (2002) Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 110(10):1559–72.

    Article  PubMed  CAS  Google Scholar 

  66. Gardella TJ, Juppner H (2001) Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol Metab 12:210–17.

    Article  PubMed  CAS  Google Scholar 

  67. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD (2000) Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82:858–64.

    Article  PubMed  CAS  Google Scholar 

  68. Geoffroy V, Kneissel M, Fournier B, Boyde A, Matthias P (2002) High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 22:6222–33.

    Article  PubMed  CAS  Google Scholar 

  69. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22(5):455–61.

    Article  PubMed  CAS  ISI  Google Scholar 

  70. Giuliani N, Pedrazzoni M, Passeri G, Girasole G (1998) Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scandinavian Journal of Rheumatology 27(1):38–41.

    Article  PubMed  CAS  ISI  Google Scholar 

  71. Gkonos PJ, London R, Hendler ED (1984) Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. New England Journal of Medicine 311(26):1683–5.

    Article  PubMed  CAS  ISI  Google Scholar 

  72. Green JR, Clezardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25(6 Suppl 1):S3–9.

    Article  PubMed  Google Scholar 

  73. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3 Suppl):840–7.

    Article  PubMed  ISI  Google Scholar 

  74. Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, et al. (1991) Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. Journal of Clinical Endocrinology & Metabolism 73(6):1309–15.

    CAS  Google Scholar 

  75. Grill V, Martin TJ (2000) Hypercalcemia of malignancy. Reviews in Endocrine & Metabolic Disorders 1(4):253–63.

    Article  CAS  Google Scholar 

  76. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, et al. (1992) Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Journal of Clinical Oncology 10(1):134–42.

    PubMed  CAS  ISI  Google Scholar 

  77. Guise TA, Garrett IR, Bonewald LF, Mundy GR (1993) Interleukin-1 receptor antagonist inhibits the hypercalcemia mediated by interleukin-1. Journal of Bone & Mineral Research 8(5):583–7.

    CAS  Google Scholar 

  78. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19:18–54.

    Article  PubMed  CAS  Google Scholar 

  79. Guise TA, Yin JJ, Mohammad KS (2003) Role of endothelin-1 in osteoblastic bone metastases. Cancer 97(3 Suppl):779–84.

    Article  PubMed  ISI  Google Scholar 

  80. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544–9.

    Article  PubMed  CAS  Google Scholar 

  81. Guise TA, Yoneda T, Yates AJ, Mundy GR (1993) The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 77(1):40–5.

    Article  PubMed  CAS  Google Scholar 

  82. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M (1986) Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem 261:12665–74.

    PubMed  CAS  Google Scholar 

  83. Henderson M, Danks J, Moseley J, Slavin J, Harris T, McKinlay M, Hopper J, Martin T (2001) Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 93:234–7.

    Article  PubMed  CAS  Google Scholar 

  84. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–53.

    Article  PubMed  CAS  Google Scholar 

  85. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O’keefe PF, Ramnaraine ML, Clohisy DR, Mantyh PW (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521–8.

    Article  PubMed  CAS  Google Scholar 

  86. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, et al. (1987) Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238(4833):1566–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  87. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 335:1785–91.

    Article  PubMed  CAS  Google Scholar 

  88. Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. Quarterly Journal of Medicine 50(200):473–81.

    PubMed  CAS  ISI  Google Scholar 

  89. Ibbotson KJ, Twardzik DR, D’souza SM, Hargreaves WR, Todaro GJ, Mundy GR (1985) Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha. Science 228(4702):1007–9.

    Article  PubMed  CAS  ISI  Google Scholar 

  90. Iguchi H, Miyagi C, Tomita K, Kawauchi S, Nozuka Y, Tsuneyoshi M, et al. (1998) Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. Journal of Clinical Endocrinology & Metabolism 83(8):2653–7.

    Article  CAS  Google Scholar 

  91. Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma T, Kimura T, Hiraga T, Ozawa H, Kono A (1996) An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 56:4040–3.

    PubMed  CAS  ISI  Google Scholar 

  92. Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, et al. (1994) Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. Journal of Clinical Endocrinology & Metabolism 79(5):1322–7.

    Article  CAS  Google Scholar 

  93. Iwamura M, Hellman J, Cockett AT, Lilja H, Gershagen S (1996) Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48:317–25.

    Article  PubMed  CAS  ISI  Google Scholar 

  94. Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S, Tsutsui H, Kaisho T, Sugihara A, Yamada N, Mukai M, Yoneda T, Okamura H, Akedo H, Terada N (2002) Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother 25Suppl 1:S52–60.

    Article  PubMed  CAS  Google Scholar 

  95. Jackson JG, Zhang X, Yoneda T, Yee D (2001) Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20:7318–25.

    Article  PubMed  CAS  ISI  Google Scholar 

  96. Johnson RA, Boyce BF, Mundy GR, Roodman GD (1989) Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 124(3):1424–7.

    Article  PubMed  CAS  ISI  Google Scholar 

  97. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277:24571–8.

    Article  PubMed  CAS  Google Scholar 

  98. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–49.

    Article  PubMed  CAS  ISI  Google Scholar 

  99. Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179–81.

    Article  PubMed  CAS  Google Scholar 

  100. Kanis JA, McCloskey EV, Powles TJ (1999) Clodronate in the treatment of neoplastic bone disease. Program and Abstracts, Second International Conference on Cancer-Induced Bone Disease 4.

    Google Scholar 

  101. Kanis JA, Urwin GH, Gray RE, Beneton MN, McCloskey EV, Hamdy NA, et al. (1987) Effects of intravenous etidronate disodium on skeletal and calcium metabolism. American Journal of Medicine 82(2A):55–70.

    Article  PubMed  CAS  ISI  Google Scholar 

  102. Klein BY, Ben-Bassat H, Breuer E, Solomon V, Golomb G (1998) Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. Journal of Cellular Biochemistry 68(2):186–94.

    Article  PubMed  CAS  ISI  Google Scholar 

  103. Klein DC, Raisz LG (1970) Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 86(6):1436–40.

    PubMed  CAS  ISI  Google Scholar 

  104. Kohno N, Kitazawa S, Fukase M, Sakoda Y, Kanbara Y, Furuya Y, et al. (1994) The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surgery Today 24(3):215–20.

    Article  PubMed  CAS  ISI  Google Scholar 

  105. Koizumi M, Ogata E (2002) Bone metabolic markers as gauges of metastasis to bone: a review. Ann Nucl Med 16:161–8.

    Article  PubMed  CAS  Google Scholar 

  106. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O’Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC (2002) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  107. Koutsilieris M (1995) Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 18:51–64.

    Article  PubMed  CAS  Google Scholar 

  108. Kovacs CS, Lanske B, Hunzelman JL, Guo J, Karaplis AC, Kronenberg HM (1996) Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. Proc Natl Acad Sci USA 93(26):15233–8.

    Article  PubMed  CAS  Google Scholar 

  109. Kremer R, Shustik C, Tabak T, Papavasiliou V, Goltzman D (1996) Parathyroid-hormone-related peptide in hematologic malignancies. American Journal of Medicine 100(4):406–11.

    Article  PubMed  CAS  ISI  Google Scholar 

  110. Kukreja SC, Rosol TJ, Wimbiscus SA, Shevrin DH, Grill V, Barengolts EI, Martin TJ (1990) Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. Endocrinology Jul 127(1):305–10.

    CAS  Google Scholar 

  111. Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W (2001) A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 37:106–13.

    Article  PubMed  CAS  Google Scholar 

  112. Li H, Seitz PK, Selvanayagam P, Rajaraman S, Cooper CW (1996) Effect of endogenously produced parathyroid hormone-related peptide on growth of a human hepatoma cell line (Hep G2). Endocrinology 137(6):2367–74.

    Article  PubMed  CAS  ISI  Google Scholar 

  113. Li X, Tomita M, Pilbeam CC, Breyer RM, Raisz LG (2002) Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. Prostaglandins Other Lipid Mediat 67(3–4):173–80.

    Article  PubMed  CAS  ISI  Google Scholar 

  114. Liapis H, Crouch EC, Grosso LE, Kitazawa S, Wick MR (1993) Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. American Journal of Pathology 143(4):1169–78.

    PubMed  CAS  ISI  Google Scholar 

  115. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET (2001) Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47:212–21.

    Article  PubMed  CAS  ISI  Google Scholar 

  116. Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97(3 Suppl):848–853.

    Article  PubMed  ISI  Google Scholar 

  117. Lipton A (2003) Bone metastases in breast cancer. Curr Treat Options Oncol 4:151–8.

    Article  PubMed  Google Scholar 

  118. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW (2002) Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99:397–406.

    Article  PubMed  CAS  ISI  Google Scholar 

  119. Luparello C, Burtis WJ, Raue F, Birch MA, Gallagher JA (1995) Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. Molecular & Cellular Endocrinology 111(2):225–32.

    Article  CAS  Google Scholar 

  120. Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–73.

    Article  PubMed  CAS  ISI  Google Scholar 

  121. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of Clinical Oncology 19(2):558–67.

    PubMed  CAS  ISI  Google Scholar 

  122. Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res 57:385–409.

    Article  PubMed  CAS  Google Scholar 

  123. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201–9.

    Article  PubMed  CAS  Google Scholar 

  124. Mareel M, Leroy A (2003) Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 83:337–76.

    PubMed  CAS  Google Scholar 

  125. Mason RS, Frankel T, Chan YL, Lissner D, Posen S (1984) Vitamin D conversion by sarcoid lymph node homogenate. Annals of Internal Medicine 100(1):59–61.

    PubMed  CAS  ISI  Google Scholar 

  126. Mastro AM, Gay CV, Welch DR (2003) The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 20:275–84.

    Article  PubMed  CAS  Google Scholar 

  127. Mercier RJ, Thompson JM, Harman GS, Messerschmidt GL (1988) Recurrent hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in Hodgkin’s disease. American Journal of Medicine 84(1):165–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  128. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F (1996) Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 271:23345–51.

    Article  PubMed  CAS  Google Scholar 

  129. Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP, et al. (2001) BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 128(22):4523–34.

    PubMed  CAS  ISI  Google Scholar 

  130. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432–6.

    PubMed  CAS  ISI  Google Scholar 

  131. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall RE, Kemp BE, Suva LJ, et al. (1987) Parathyroid hormone-related protein purified from a human lung cancer cell line. Proceedings of the National Academy of Sciences of the United States of America 84(14):5048–52.

    Article  PubMed  CAS  ISI  Google Scholar 

  132. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  133. Mundy GR, Rick ME, Turcotte R, Kowalski MA (1978) Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role of an osteoclast activating factor-like substance and a mechanism of action for glucocorticoid therapy. American Journal of Medicine 65(4):600–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  134. Mundy GR, Wilkinson R, Heath DA (1983) Comparative study of available medical therapy for hypercalcemia of malignancy. American Journal of Medicine 74(3):421–32.

    Article  PubMed  CAS  ISI  Google Scholar 

  135. Mundy GR. Hypercalcemia (1995) In: Mundy GR, editor. Bone remodeling and its disorders. London: Martin Dunitz:88–103.

    Google Scholar 

  136. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–93.

    Article  PubMed  CAS  Google Scholar 

  137. Nagai M, Kyakumoto S, Sato N (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 269(2):532–6.

    Article  PubMed  CAS  Google Scholar 

  138. Nakata A, Tsujimura T, Sugihara A, Okamura H, Iwasaki T, Shinkai K, Iwata N, Kakishita E, Akedo H, Terada N (1999) Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res 19:4131–8.

    PubMed  CAS  ISI  Google Scholar 

  139. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110–16.

    Article  PubMed  CAS  Google Scholar 

  140. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, Daliani DD, Schulman CC, Carducci MA (2003) Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143–9.

    Article  PubMed  CAS  Google Scholar 

  141. Nemeth EF (2002) Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 8:2077–87.

    Article  PubMed  CAS  Google Scholar 

  142. Nielsen PK, Rasmussen AK, Feldt-Rasmussen U, Brandt M, Christensen L, Olgaard K (1996) Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. Journal of Clinical Endocrinology & Metabolism 81(10):3793–6.

    Article  CAS  Google Scholar 

  143. Nussbaum SR, Gaz RD, Arnold A (1990) Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. New England Journal of Medicine 323(19):1324–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  144. Oehler MK, Rees MC, Bicknell R (2000) Steroids and the endometrium. Curr Med Chem 7:543–60.

    PubMed  CAS  Google Scholar 

  145. Orr W, Varani J, Gondex MK, Ward PA, Mundy GR (1978) Chemotactic responses of tumor cells to products of resorbing bone. Science 203:176–9.

    Article  ISI  Google Scholar 

  146. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–72.

    Article  PubMed  CAS  Google Scholar 

  147. Ozbas S, Dafydd H, Purushotham AD (2003) Bone marrow micrometastasis in breast cancer. Br J Surg 90:290–301.

    Article  PubMed  CAS  Google Scholar 

  148. Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1:571–2.

    Article  Google Scholar 

  149. Philbrick WM, Dreyer BE, Nakchbandi IA, Karaplis AC (1998) Parathyroid hormone-related protein is required for tooth eruption. Proc Natl Acad Sci USA 95(20):11846–51.

    Article  PubMed  CAS  Google Scholar 

  150. Pirola CJ, Wang HM, Strgacich MI, Kamyar A, Cercek B, Forrester JS, et al. (1994) Mechanical stimuli induce vascular parathyroid hormone-related protein gene expression in vivo and in vitro. Endocrinology 134(5):2230–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  151. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. Journal of Clinical Investigation 104(10):1363–74.

    Article  PubMed  CAS  ISI  Google Scholar 

  152. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res 51:3059–61.

    PubMed  CAS  ISI  Google Scholar 

  153. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. British Journal of Cancer 72(5):1289–93.

    PubMed  CAS  ISI  Google Scholar 

  154. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Annals of Internal Medicine 112(7):499–504.

    PubMed  CAS  ISI  Google Scholar 

  155. Reddi AH, Roodman D, Freeman C, Mohla S (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18:190–4.

    Article  PubMed  CAS  Google Scholar 

  156. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, et al. (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Research 60(21):6001–7.

    PubMed  CAS  ISI  Google Scholar 

  157. Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova NSh, Mikhailov SN, Ingle JN, Spelsberg TC (2002) Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat 71:257–68.

    Article  PubMed  CAS  Google Scholar 

  158. Remuzzi G, Perico N, Benigni A (2003) New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 1:986–1001.

    Article  CAS  Google Scholar 

  159. Riggs BL, Hartmann LC (2003) Selective estrogenreceptor modulators — mechanisms of action and application to clinical practice. N Engl J Med 348:618–29.

    Article  PubMed  CAS  Google Scholar 

  160. Rizzoli R, Pache JC, Didierjean L, Burger A, Bonjour JP (1994) A thymoma as a cause of true ectopic hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism 79(3):912–15.

    Article  CAS  Google Scholar 

  161. Roodman GD (2003) Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 97(3 Suppl):733–8.

    Article  ISI  Google Scholar 

  162. Roodman GD (2001) Biology of osteoclast activation in cancer. J Clin Oncol 19:3562–71.

    PubMed  CAS  Google Scholar 

  163. Rosenbaum E, Carducci MA (2003) Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Expert Opin Pharmacother 4:875–87.

    Article  PubMed  CAS  Google Scholar 

  164. Rosenthal N, Insogna KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF (1985) Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. Journal of Clinical Endocrinology & Metabolism 60(1):29–33.

    CAS  Google Scholar 

  165. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL (2003). Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34:646–53.

    Article  PubMed  Google Scholar 

  166. Roudier MP, Vessella H, True LD, et al. (2003) Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 20:171–80.

    Article  PubMed  CAS  Google Scholar 

  167. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 5:97–106.

    Article  Google Scholar 

  168. Sabatini M, Boyce B, Aufdemorte T, Bonewald L, Mundy GR (1988) Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 85(14):5235–9.

    Article  PubMed  CAS  Google Scholar 

  169. Safadi FF, Xu J, Smock SL, Kanaan RA, Selim AH, Odgren PR, Marks SC Jr, Owen TA, Popoff SN (2003) Expression of connective tissue growth factor in bone: Its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J Cell Physiol1 96:51–62.

    Article  CAS  Google Scholar 

  170. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM (2000) Extracellular calcium-sensing receptor (CaR) expression and its potential role in parathyroid hormone-related peptide (PTHrP) secretion in the H-500 rat Leydig cell model of humoral hypercalcemia of malignancy. Biochem Biophys Res Commun 269:427–32.

    Article  PubMed  CAS  Google Scholar 

  171. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T (1995) The bisphosphonate residronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551–7.

    PubMed  CAS  ISI  Google Scholar 

  172. Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kurosawa H, Tsushima T, Shizume K (1989) Parathyroid hormone-related protein and interleukin-1 alpha synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 124(5):2172–8.

    PubMed  CAS  ISI  Google Scholar 

  173. Sato K, Onuma E, Yocum RC, Ogata E (2003) Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol. 30(5 Suppl 16):167–73.

    Article  PubMed  CAS  Google Scholar 

  174. Schluter KD, Katzer C, Piper HM (2001) A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol1 32:427–32.

    Article  Google Scholar 

  175. Schluter KD, Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormonerelated peptide. Cardiovascular Research 37(1):34–41.

    Article  PubMed  CAS  ISI  Google Scholar 

  176. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100:7737–42.

    Article  PubMed  CAS  Google Scholar 

  177. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F (1994) Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Annals of Internal Medicine 121(9):633–40.

    PubMed  CAS  ISI  Google Scholar 

  178. Seymour JF, Grill V, Martin TJ, Lee N, Firkin F (1993) Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein. Leukemia 7(10):1672–5.

    PubMed  CAS  ISI  Google Scholar 

  179. Shakespeare W, Yang M, Bohacek R, Cerasoli F, Stebbins K, Sundaramoorthi R, Azimioara M, Vu C, Pradeepan S, Metcalf C 3rd, Haraldson C, Merry T, Dalgarno D, Narula S, Hatada M, Lu X, van Schravendijk MR, Adams S, Violette S, Smith J, Guan W, Bartlett C, Herson J, Iuliucci J, Weigele M, Sawyer T (2000) Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci USA 97:9373–8.

    Article  PubMed  CAS  Google Scholar 

  180. Sherry MM, Greco FA, Johnson DH, Hainsworth JD (1986) Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med. 81:381–6.

    Article  PubMed  CAS  Google Scholar 

  181. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–19.

    Article  PubMed  CAS  ISI  Google Scholar 

  182. Singer FR, Ritch PS, Lad TE, Ringenberg QS, Schiller JH, Recker RR, et al. (1991) Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. [erratum appears in Arch Intern Med (1991) Oct 151(10):2008]. Archives of Internal Medicine 151(3):471–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  183. Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, Meric F, Hortobagyi GN (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8:241–51.

    Article  PubMed  ISI  Google Scholar 

  184. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N (2003) Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. J Urol1 69:2008–12.

    Article  CAS  Google Scholar 

  185. Smith MR (2003) Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev 29:211–18.

    Article  PubMed  Google Scholar 

  186. Southby J, Kissin MW, Danks JA, Hayman JA, Moseley JM, Henderson MA, et al. (1990) Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Research 50(23):7710–16.

    PubMed  CAS  ISI  Google Scholar 

  187. Spelsberg TC, Subramaniam M, Riggs BL, Khosla S (1999) The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol 13:819–28.

    Article  PubMed  CAS  Google Scholar 

  188. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE (1981) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. New England Journal of Medicine 303(24):1377–83.

    Google Scholar 

  189. Strewler GJ, Budayr AA, Clark OH, Nissenson RA (1993) Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient. Journal of Clinical Endocrinology & Metabolism 76(5):1373–5.

    Article  CAS  Google Scholar 

  190. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, et al. (1987) Parathyroid hormonelike protein from human renal carcinoma cells. Structural and functional homology with parathyroid hormone. Journal of Clinical Investigation 80(6):1803–7.

    Article  PubMed  CAS  ISI  Google Scholar 

  191. Strewler GJ (2000) The physiology of parathyroid hormone-related protein. New England Journal of Medicine 342(3):177–85.

    Article  PubMed  CAS  ISI  Google Scholar 

  192. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–57.

    Article  PubMed  CAS  Google Scholar 

  193. Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Eknoyan G, Martinez-Maldonado M (1970) Actue treatment of hypercalcemia with furosemide. New England Journal of Medicine 283(16):836–40.

    Article  PubMed  CAS  ISI  Google Scholar 

  194. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, Diefenbach-Jagger H, et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237(4817):893–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  195. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA (1994) Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 15:161–6.

    Article  PubMed  CAS  ISI  Google Scholar 

  196. Teti A, Migliaccio S, Baron R (2002) The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcif Tissue Int 71:293–9.

    Article  PubMed  CAS  Google Scholar 

  197. Thiebaud D, Jacquet AF, Burckhardt P (1990) Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Archives of Internal Medicine 150(10):2125–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  198. Thiede MA, Daifotis AG, Weir EC, Brines ML, Burtis WJ, Ikeda K, et al. (1990) Intrauterine occupancy controls expression of the parathyroid hormone-related peptide gene in preterm rat myometrium. Proc Natl Acad Sci USA 87(18):6969–73.

    Article  PubMed  CAS  Google Scholar 

  199. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinol 140:4451–8.

    Article  CAS  ISI  Google Scholar 

  200. Tisdale MJ. Cancer (2002) Cachexia in cancer patients. Nat Rev 2:862–71.

    CAS  Google Scholar 

  201. Tokuda H, Kozawa O, Harada A, Uematsu T (1998) Tiludronate inhibits interleukin-6 synthesis in osteoblasts: inhibition of phospholipase D activation in MC3T3-E1 cells. Journal of Cellular Biochemistry 69(3):252–9.

    Article  PubMed  CAS  ISI  Google Scholar 

  202. Torring O, Turner RT, Carter WB, Firek AF, Jacobs CA, Health H 3rd (1992) Inhibition by human interleukin-1 alpha of parathyroid hormone-related peptide effects on renal calcium and phosphorus metabolism in the rat. Endocrinology 131(1):5–13.

    Article  PubMed  CAS  ISI  Google Scholar 

  203. Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med. 115(2):115–21.

    Article  PubMed  CAS  Google Scholar 

  204. Tuttle KR, Kunau RT, Loveridge N, Mundy GR (1991) Altered renal calcium handling in hypercalcemia of malignancy Journal of the American Society of Nephrology 2(2):191–9.

    PubMed  CAS  ISI  Google Scholar 

  205. Ueno M, Ban S, Nakanoma T, Tsukamoto T, Nonaka S, Hirata R, et al. (2000) Hypercalcemia in a patient with renal cell carcinoma producing parathyroid hormonerelated protein and interleukin-6 International Journal of Urology 7(6):239–42.

    Article  PubMed  CAS  ISI  Google Scholar 

  206. Uy HL, Guise TA, De La Mata J, Taylor SD, Story BM, Dallas MR, et al. (1995) Effects of parathyroid hormone (PTH)-related protein and PTH on osteoclasts and osteoclast precursors in vivo Endocrinology 136(8):3207–12.

    Article  PubMed  CAS  ISI  Google Scholar 

  207. Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, et al. (1997) Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo Cancer Research 57(15):3194–9.

    PubMed  CAS  ISI  Google Scholar 

  208. van der Pluijm G, Lowik C, Papapoulos S (2000) Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem Cancer Treat Rev 26:11–27.

    Article  PubMed  CAS  Google Scholar 

  209. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C (2001) Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 16:1077–91.

    Article  PubMed  Google Scholar 

  210. van der Pluijm G, Vloedgraven HJM, Ivanov B, Robey FA, Grzesik WJ, Robey PG, Papapoulos SE, Löwik CWGM (1996) Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res. 56:1948–55.

    PubMed  Google Scholar 

  211. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, Martin TJ (1992) Localization of parathyroid hormone-related protein mRNA expression and metastatic lesions by in situ hybridization. J Bone Miner Res 7:971–80.

    PubMed  CAS  Google Scholar 

  212. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochemical & Biophysical Research Communications 291(3):680–6.

    Article  CAS  Google Scholar 

  213. Wada S, Yasuda S, Nagai T, Maeda T, Kitahama S, Suda S, et al. (2001) Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. Endocrinology 142(4):1471–8.

    Article  PubMed  CAS  ISI  Google Scholar 

  214. Wakefield LM, Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12:22–9.

    Article  PubMed  CAS  Google Scholar 

  215. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552:61–85.

    PubMed  CAS  Google Scholar 

  216. Weissglas M, Schamhart D, Lowik C, Papapoulos S, Vos P, Kurth KH (1995) Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. Journal of Urology 153(3 Pt 1):854–7.

    PubMed  CAS  ISI  Google Scholar 

  217. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–61.

    Article  PubMed  CAS  Google Scholar 

  218. Woodhouse EC, Chuaqui RF, Liotta LA (1997) General mechanisms of metastasis. Cancer 80(8 Suppl):1529–37.

    Article  PubMed  CAS  ISI  Google Scholar 

  219. Wysolmerski JJ, Broadus AE, Zhou J, Fuchs E, Milstone LM, Philbrick WM (1994) Overexpression of parathyroid hormone-related protein in the skin of transgenic mice interferes with hair follicle development. Proc Natl Acad Sci USA 91(3):1133–7.

    Article  PubMed  CAS  Google Scholar 

  220. Wysolmerski JJ, Carucci JM, Broadus AE, Philbrick WM (1994) PTH and PTHrP antagonize mammary gland growth and development in transgenic mice. Journal of Bone & Mineral Research 9(Suppl 1):S121.

    Google Scholar 

  221. Wysolmerski JJ, Philbrick WM, Dunbar ME, Lanske B, Kronenberg H, Broadus AE (1998) Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 125(7):1285–94.

    PubMed  CAS  ISI  Google Scholar 

  222. Yamaguchi T, Chattopadhyay N, Brown EM (2000) G protein-coupled extracellular Ca2+ (Ca2+o)-sensing receptor (CaR): roles in cell signaling and control of diverse cellular functions. Adv Pharmacol 47:209–53.

    Article  PubMed  CAS  Google Scholar 

  223. Yamamoto M, Harm SC, Grasser WA, Thiede MA (1992) Parathyroid hormone-related protein in the rat urinary bladder: a smooth muscle relaxant produced locally in response to mechanical stretch. Proc Natl Acad Sci USA 89(12):5326–30.

    Article  PubMed  CAS  Google Scholar 

  224. Yates AJ, Boyce BF, Favarato G, Aufdemorte TB, Marcelli C, Kester MB, et al. (1992) Expression of human transforming growth factor alpha by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increased osteoclastic bone resorption. Journal of Bone & Mineral Research 7(7):847–53.

    Article  CAS  Google Scholar 

  225. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62:917–23.

    PubMed  CAS  ISI  Google Scholar 

  226. Yin JJ, Mohammad KS, Käkönen S-M, Harris S, Wu-Wong RJ, Wessale J, Padley RJ, Garrett IR, Chirgwin JM, Guise TA (2003) A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 100(19):10588–9.

    Article  CAS  Google Scholar 

  227. Yin JJ, Selander KS, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massague J, Mundy GR, Guise TA (1999) TGFb signaling blockade inhibits parathyroid hormone-related protein secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197–206.

    Article  PubMed  CAS  Google Scholar 

  228. Yoneda T (2000) Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 5:75–81.

    Article  PubMed  CAS  Google Scholar 

  229. Yoshimoto K, Yamasaki R, Sakai H, Tezuka U, Takahashi M, Iizuka M, et al. (1989) Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. Journal of Clinical Endocrinology & Metabolism 68(5):976–81.

    Article  CAS  Google Scholar 

  230. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. (2001) Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. Journal of Clinical Endocrinology & Metabolism 86(2):888–94.

    Article  CAS  Google Scholar 

  231. Zhao W, Byrne MH, Boyce BF, Krane SM (1999) Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest 103:517–24.

    Article  PubMed  CAS  Google Scholar 

  232. Zudaire E, Martinez A, Cuttitta F (2003) Adrenomedullin and cancer. Regul Pept 112:175–83.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Gregory A. Clines
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John M. Chirgwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theresa A. Guise
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of BioStructure and Function, University of Connecticut Health Center, Farmington, CT, USA

    Felix Bronner PhD

  2. Department of Pharmacology, University of Connecticut Health Center, Farmington, CT, USA

    Felix Bronner PhD

  3. Department of Biology, University of Delaware, Newark, DE, USA

    Mary C Farach-Carson PhD

  4. Division of Endocrinology and Metabolism, Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, GA, USA

    Janet Rubin MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

Clines, G.A., Chirgwin, J.M., Guise, T.A. (2005). Skeletal Complications of Malignancy: Central Role for the Osteoclast. In: Bronner, F., Farach-Carson, M.C., Rubin, J. (eds) Bone Resorption. Topics in Bone Biology, vol 2. Springer, London. https://doi.org/10.1007/1-84628-016-8_9

Download citation

  • DOI: https://doi.org/10.1007/1-84628-016-8_9

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-812-1

  • Online ISBN: 978-1-84628-016-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation